| Daniel Tucker, PT | |
|
344 F St, Suite 300, Chula Vista, CA 91910-2645 | |
| (619) 585-4080 | |
| (619) 427-4572 |
| Full Name | Daniel Tucker |
|---|---|
| Gender | Male |
| Speciality | Physical Therapy |
| Experience | 30 Years |
| Location | 344 F St, Chula Vista, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023332525 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | PT 20759 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sharp Rees-stealy Medical Group Inc | 8628972759 | 772 |
News Archive
University of Toronto researchers have developed a series of techniques to create a variety of very active iron-based catalysts necessary to produce the alcohols and amines used in the drug and perfume industry. The new synthetic methods promise to be safer and more economical and environmentally friendly than traditional industrial processes.
Grifols, a global healthcare company and leading producer of plasma therapies, and Alkahest, a Redwood City, California based, privately held biopharmaceutical company founded upon the pioneering work of Dr. Tony Wyss-Coray and other leading scientists at Stanford University, today announced that they have signed definitive agreements whereby Grifols will make a major equity investment in Alkahest, and the companies will work together to develop novel plasma-based products for the treatment of cognitive decline in aging and disorders of the central nervous system (CNS), including Alzheimer's.
Zymeworks Inc. today announced that it has entered into a licensing and collaboration agreement with ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, to develop an undisclosed number of novel bi-specific antibody oncology therapeutics using Zymeworks' proprietary Azymetric platform. Bi-specific antibodies have the potential to provide improved outcomes for patients by simultaneously targeting two tumor associated antigens to induce a synergistic therapeutic response.
Queensland government's builder - QBuild's handling of asbestos at a north Queensland school is inappropriate says a report. After a painter at the Mackay West State School identified asbestos in December 2009, the QBuild workers came in to decontaminate the area but they did not wear protective clothing and removed dust with a domestic vacuum cleaner.
› Verified 2 days ago
| Provider Name | Sharp Rees-stealy Medical Group Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1285616177 PECOS PAC ID: 8628972759 Enrollment ID: O20031120000996 |
News Archive
University of Toronto researchers have developed a series of techniques to create a variety of very active iron-based catalysts necessary to produce the alcohols and amines used in the drug and perfume industry. The new synthetic methods promise to be safer and more economical and environmentally friendly than traditional industrial processes.
Grifols, a global healthcare company and leading producer of plasma therapies, and Alkahest, a Redwood City, California based, privately held biopharmaceutical company founded upon the pioneering work of Dr. Tony Wyss-Coray and other leading scientists at Stanford University, today announced that they have signed definitive agreements whereby Grifols will make a major equity investment in Alkahest, and the companies will work together to develop novel plasma-based products for the treatment of cognitive decline in aging and disorders of the central nervous system (CNS), including Alzheimer's.
Zymeworks Inc. today announced that it has entered into a licensing and collaboration agreement with ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, to develop an undisclosed number of novel bi-specific antibody oncology therapeutics using Zymeworks' proprietary Azymetric platform. Bi-specific antibodies have the potential to provide improved outcomes for patients by simultaneously targeting two tumor associated antigens to induce a synergistic therapeutic response.
Queensland government's builder - QBuild's handling of asbestos at a north Queensland school is inappropriate says a report. After a painter at the Mackay West State School identified asbestos in December 2009, the QBuild workers came in to decontaminate the area but they did not wear protective clothing and removed dust with a domestic vacuum cleaner.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Daniel Tucker, PT 344 F St, Suite 300, Chula Vista, CA 91910-2645 Ph: (619) 585-4080 | Daniel Tucker, PT 344 F St, Suite 300, Chula Vista, CA 91910-2645 Ph: (619) 585-4080 |
News Archive
University of Toronto researchers have developed a series of techniques to create a variety of very active iron-based catalysts necessary to produce the alcohols and amines used in the drug and perfume industry. The new synthetic methods promise to be safer and more economical and environmentally friendly than traditional industrial processes.
Grifols, a global healthcare company and leading producer of plasma therapies, and Alkahest, a Redwood City, California based, privately held biopharmaceutical company founded upon the pioneering work of Dr. Tony Wyss-Coray and other leading scientists at Stanford University, today announced that they have signed definitive agreements whereby Grifols will make a major equity investment in Alkahest, and the companies will work together to develop novel plasma-based products for the treatment of cognitive decline in aging and disorders of the central nervous system (CNS), including Alzheimer's.
Zymeworks Inc. today announced that it has entered into a licensing and collaboration agreement with ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, to develop an undisclosed number of novel bi-specific antibody oncology therapeutics using Zymeworks' proprietary Azymetric platform. Bi-specific antibodies have the potential to provide improved outcomes for patients by simultaneously targeting two tumor associated antigens to induce a synergistic therapeutic response.
Queensland government's builder - QBuild's handling of asbestos at a north Queensland school is inappropriate says a report. After a painter at the Mackay West State School identified asbestos in December 2009, the QBuild workers came in to decontaminate the area but they did not wear protective clothing and removed dust with a domestic vacuum cleaner.
› Verified 2 days ago
Nicole M Irizarry, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 510 E Naples St, Chula Vista, CA 91911 Phone: 619-421-6083 | |
Joseph Edward Bailey, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 955 Lane Ave, #201, Chula Vista, CA 91914 Phone: 619-421-9521 Fax: 619-421-9568 | |
Dr. Stacy Haller, PT, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 1040 Tierra Del Rey Ste 107, Chula Vista, CA 91910 Phone: 619-500-5884 | |
David Sebastian Mignea, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 320 Broadway Ste 2, Chula Vista, CA 91910 Phone: 619-422-0404 Fax: 619-422-4153 | |
Ms. Kara W. Barnett, P.T. Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 891 Kuhn Dr, Ste. 101, Chula Vista, CA 91914 Phone: 619-656-6470 Fax: 619-656-6614 | |
Mrs. Afsoon Roshan Johnston, MSPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 251 Landis Ave, Chula Vista, CA 91910 Phone: 619-498-8450 |